Market Cap 262.28M
Revenue (ttm) 236.20M
Net Income (ttm) -5.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2.27%
Debt to Equity Ratio 1.98
Volume 6,141,400
Avg Vol 5,908,274
Day's Range N/A - N/A
Shares Out 277.11M
Stochastic %K 50%
Beta 0.19
Analysts Strong Sell
Price Target $3.80

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 617 871 2098
Fax: 617 871 2099
Address:
245 First Street, Suite 1400, Cambridge, United States
john1993
john1993 Sep. 13 at 7:30 AM
$AKBA John buttler literally kept the stock price above 3.5 for 30 trading days july 2025 so he can get his bonus… that’s the only explanation… this bastard he’s so sick
0 · Reply
three_zero
three_zero Sep. 13 at 4:38 AM
$AKBA It was going to happen sooner or later. The guy that covers the weekend shift for the pithy account had a few screws loose. He never followed the “esteemed trial lawyer” bio at all.
0 · Reply
Buythehornz67
Buythehornz67 Sep. 13 at 12:46 AM
$AKBA 🎉Hey Pilthy… BYE LOL LMAO 😂 🤣🎉
1 · Reply
Akba_BO
Akba_BO Sep. 12 at 11:50 PM
$AKBA Did the shorting low IQ cowards cause @mr_pithy to be banned?
2 · Reply
trader20201414
trader20201414 Sep. 12 at 5:27 PM
$AKBA Wow!!. Morally, this is beyond disgusting, encouraging someone to kill themselves is a whole different level of low. I already knew you lacked basic decency, but I never thought you’d stoop this far. Your true colors are showing, and they say everything anyone needs to know about your character. You are my friend a certified clown who lost the narrative.
3 · Reply
Fruterin
Fruterin Sep. 12 at 5:12 PM
$AKBA If Vocal releases excellent results, what share price can we expect by the end of the year?
5 · Reply
Noname2022
Noname2022 Sep. 12 at 5:09 PM
0 · Reply
Paperglider
Paperglider Sep. 12 at 3:33 AM
$AKBA If any of you plan on attending this meeting, please summarize key takeaways. You can register and watch this meeting virtually. Follow the link below https://events.medscapelive.org/website/97765/#home
1 · Reply
MB76
MB76 Sep. 12 at 1:19 AM
$AKBA Citadel playing games big time today!!! They sold 74% of today’s shares via synthetic shares and covered them via DP!!!! Ask why? LOL, not getting our shares!!!! Keep paying your troll to post BS from his 20+ accounts!!!!!
0 · Reply
Byrdman76
Byrdman76 Sep. 12 at 1:11 AM
1 · Reply
Latest News on AKBA
Akebia initiated with a Buy at WestPark Capital

2026-09-08T12:25:25.000Z - 4 days ago

Akebia initiated with a Buy at WestPark Capital


Akebia Therapeutics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 weeks ago

Akebia Therapeutics Earnings Call Transcript: Q2 2026


Akebia Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 weeks ago

Akebia Therapeutics Earnings release: Q2 2026


Akebia Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 weeks ago

Akebia Therapeutics Quarterly report: Q2 2026


Akebia initiates ebribafusp basket trial

2026-08-03T12:20:30.000Z - 5 weeks ago

Akebia initiates ebribafusp basket trial


Akebia announces VOICE trial met predefined stopping criteria

2026-06-30T12:31:42.000Z - 2 months ago

Akebia announces VOICE trial met predefined stopping criteria


Akebia Therapeutics Transcript: AGM 2026

Jun 17, 2026, 10:00 AM EDT - 2 months ago

Akebia Therapeutics Transcript: AGM 2026


Akebia announces new Vafseo patent

2026-06-10T12:28:51.000Z - 3 months ago

Akebia announces new Vafseo patent


Akebia Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Earnings Call Transcript: Q1 2026


Akebia Therapeutics Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Earnings release: Q1 2026


Akebia Therapeutics Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Quarterly report: Q1 2026


Akebia Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Proxy statement: Proxy filing


Akebia Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Proxy statement: Proxy filing


Akebia Therapeutics Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 5 months ago

Akebia Therapeutics Proxy statement: Proxy filing


Akebia doses first participants in AKB-9090 trial

2026-04-13T12:52:17.000Z - 5 months ago

Akebia doses first participants in AKB-9090 trial


Akebia Therapeutics Transcript: R&D Day 2026

Apr 2, 2026, 10:00 AM EDT - 5 months ago

Akebia Therapeutics Transcript: R&D Day 2026


Akebia Therapeutics Slides: FY 2026

Apr 2, 2026, 10:00 AM EDT - 5 months ago

Akebia Therapeutics Slides: FY 2026


Akebia Therapeutics Slides: Corporate presentation

Feb 27, 2026, 6:00 AM EST - 6 months ago

Akebia Therapeutics Slides: Corporate presentation


Akebia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Akebia Therapeutics Earnings Call Transcript: Q4 2025


Akebia Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Akebia Therapeutics Annual report: Q4 2025


Akebia Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Akebia Therapeutics Earnings release: Q4 2025


Akebia price target lowered to $4 from $5 at BTIG

2026-02-25T12:25:29.000Z - 6 months ago

Akebia price target lowered to $4 from $5 at BTIG


Akebia price target lowered to $4 from $6 at Piper Sandler

2026-02-06T11:56:25.000Z - 7 months ago

Akebia price target lowered to $4 from $6 at Piper Sandler


Akebia announces corporate updates, 2026 pipeline outlook

2026-01-12T13:52:21.000Z - 8 months ago

Akebia announces corporate updates, 2026 pipeline outlook


Q32 Bio sells complement inhibitor ADX-097 to Akebia

2025-12-01T12:05:21.000Z - 9 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia

QTTB


Akebia Announces Establishment of Rare Kidney Disease Pipeline

Dec 1, 2025, 7:00 AM EST - 9 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline


Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 9 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

QTTB


Akebia Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

Akebia Therapeutics Earnings Call Transcript: Q3 2025


Akebia Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

Akebia Therapeutics Quarterly report: Q3 2025


Akebia Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 10 months ago

Akebia Therapeutics Earnings release: Q3 2025


Akebia Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 10 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences


Akebia price target lowered to $6 from $8 at H.C. Wainwright

2025-10-30T10:11:16.000Z - 10 months ago

Akebia price target lowered to $6 from $8 at H.C. Wainwright


Akebia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q2 2025


Akebia Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Quarterly report: Q2 2025


Akebia Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings release: Q2 2025


Akebia Therapeutics Slides: Corporate Presentation

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Slides: Corporate Presentation


Akebia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q1 2025


Akebia Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Quarterly report: Q1 2025


Akebia Therapeutics Earnings release: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings release: Q1 2025


Akebia Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Proxy statement: Proxy Filing


Akebia Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Proxy statement: Proxy Filing


Akebia Therapeutics Earnings Call Transcript: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q4 2024


Akebia Therapeutics Annual report: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Annual report: Q4 2024


Akebia Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings release: Q4 2024


Akebia Therapeutics Slides: Investor Presentation

Jan 21, 2025, 7:00 AM EST - 1 year ago

Akebia Therapeutics Slides: Investor Presentation


Akebia Therapeutics Slides: FY 2025

Jan 16, 2025, 10:30 AM EST - 1 year ago

Akebia Therapeutics Slides: FY 2025


john1993
john1993 Sep. 13 at 7:30 AM
$AKBA John buttler literally kept the stock price above 3.5 for 30 trading days july 2025 so he can get his bonus… that’s the only explanation… this bastard he’s so sick
0 · Reply
three_zero
three_zero Sep. 13 at 4:38 AM
$AKBA It was going to happen sooner or later. The guy that covers the weekend shift for the pithy account had a few screws loose. He never followed the “esteemed trial lawyer” bio at all.
0 · Reply
Buythehornz67
Buythehornz67 Sep. 13 at 12:46 AM
$AKBA 🎉Hey Pilthy… BYE LOL LMAO 😂 🤣🎉
1 · Reply
Akba_BO
Akba_BO Sep. 12 at 11:50 PM
$AKBA Did the shorting low IQ cowards cause @mr_pithy to be banned?
2 · Reply
trader20201414
trader20201414 Sep. 12 at 5:27 PM
$AKBA Wow!!. Morally, this is beyond disgusting, encouraging someone to kill themselves is a whole different level of low. I already knew you lacked basic decency, but I never thought you’d stoop this far. Your true colors are showing, and they say everything anyone needs to know about your character. You are my friend a certified clown who lost the narrative.
3 · Reply
Fruterin
Fruterin Sep. 12 at 5:12 PM
$AKBA If Vocal releases excellent results, what share price can we expect by the end of the year?
5 · Reply
Noname2022
Noname2022 Sep. 12 at 5:09 PM
0 · Reply
Paperglider
Paperglider Sep. 12 at 3:33 AM
$AKBA If any of you plan on attending this meeting, please summarize key takeaways. You can register and watch this meeting virtually. Follow the link below https://events.medscapelive.org/website/97765/#home
1 · Reply
MB76
MB76 Sep. 12 at 1:19 AM
$AKBA Citadel playing games big time today!!! They sold 74% of today’s shares via synthetic shares and covered them via DP!!!! Ask why? LOL, not getting our shares!!!! Keep paying your troll to post BS from his 20+ accounts!!!!!
0 · Reply
Byrdman76
Byrdman76 Sep. 12 at 1:11 AM
1 · Reply
john1993
john1993 Sep. 11 at 11:32 PM
$AKBA that’s so true… john butler is motherfuker that runs this company as his ATM
1 · Reply
et1000
et1000 Sep. 11 at 11:17 PM
Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $ROKU $AKBA $SGMO Wild
0 · Reply
skagnetti13
skagnetti13 Sep. 11 at 10:51 PM
1 · Reply
Harrisford222
Harrisford222 Sep. 11 at 10:41 PM
$AKBA the only value JB drives is cash into HIS POCKETS
1 · Reply
trader20201414
trader20201414 Sep. 11 at 10:18 PM
$AKBA quotes 🤣 🤣 🤣 2022 — John Butler: “We plan to focus on Auryxia commercial success while exploring our earlier stage assets and pursuing other value creating business opportunities.” The Q1 release itself was titled around a strategic focus to “deliver shareholder value.” � Akebia Therapeutics +1 2023 — John Butler: “We believe that the value we’ve driven in the company far outweighs our current market cap.” He added that maintaining Nasdaq would help Akebia “maximize shareholder value.” � Akebia Therapeutics 2023 — John Butler: Regarding the proposed reverse split: “We feel it is crucial to delivering shareholder value to secure the approval to effect a reverse stock split if necessary.” � Akebia Therapeutics 2025 — John Butler: “We believe our commercial products and pipeline have the potential to generate significant shareholder value.” � Akebia Therapeutics 2026 — John Butler: Vafseo adoption and the pipeline “can drive significant shareholder value this year and beyond.” �
0 · Reply
Jeko44
Jeko44 Sep. 11 at 8:43 PM
$AKBA Ah, so the lowlife keyboard warrior @noname2022 has blocked me for calling him out on his disgustingly insensitive post this afternoon. More evidence of his character as a human. Sad person
3 · Reply
billyl
billyl Sep. 11 at 8:09 PM
$AKBA Soon… may be Nov-Dec?! BENZINGA. Sep-08-2026 11:38 a.m. ET WestPark Capital analyst Ed Arce initiates coverage on Akebia Therapeutics (AKBA) with a Buy rating and announces Price Target of $4.5.
0 · Reply
Noname2022
Noname2022 Sep. 11 at 7:57 PM
$AKBA Pairings with Purpose: Vafseo with red wine, Auryxia with white, shareholder losses with anything over 80 proof
1 · Reply
Noname2022
Noname2022 Sep. 11 at 7:49 PM
$AKBA I’d be lying if I said I wasn’t enjoying watching the true believers finally crack
1 · Reply
Magic_Money
Magic_Money Sep. 11 at 7:48 PM
$AKBA A little insight into whales and super investors. Three super investors are in AKBA, two added shares resently. Whales are accumulating overall. Should hear some positive news soon considering what happened with resent volume spike.
1 · Reply
KarlDieGlatze
KarlDieGlatze Sep. 11 at 6:02 PM
$AKBA Those 1:1 Wells Fargo and connected other person/entity meetings continues to not bear fruit excluding that glimmer of hope breaking and holding $1.00 that one day. The fact that all these firms with + $4 targets for a year or longer continue to have ill effect is bizarre minimally. There is something really broken here, this is for sure. What I want and expect is the extension of a new two year Tdapa pricing runway, or I'm out. Butler is a DISASTER.
0 · Reply